Studies blood samples to find causes and protection against heart artery disease
Compares blood samples from people with and without heart artery disease, aged 21 to 99.
Plain-language title generated from the registry record
Registry title: Extremes of Coronary Artery Disease and Normality:CAD Extremes
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 99 years old?
Source: NCT05775445, who can take part
Where in Singapore
- National Heart Centre SingaporeSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Heart Centre Singapore
- Trial code
- NCT05775445
- Record updated
- 21 February 2024
- Original description
In the field of cardiovascular medicine, there are two differing groups of patients that remain puzzling to clinicians: patients who are not expected to have coronary artery disease (CAD) yet are diagnosed with significant CAD; and those who are have multiple risk factors for CAD but do not have CAD. Bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. Prior work has identified multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis. The investigators hypothesize there are different molecular markers that confer protection or increased risk for CAD, some of which may be similar to bats. Thus, the aim of this study is to identify molecular markers that contribute to or are protective against acute coronary syndrome (ACS) through analyzing the genetics, peripheral blood and atherosclerotic samples from both extreme patient groups using single-cell RNA sequencing and multi-omics approach. In addition, novel anti-atherosclerotic mechanisms and factors from bat studies will be assessed in the human samples. Identification of novel targets that prevent or cause CAD has the potential to aid in the early identification of high-risk patients and development of new therapeutics to combat this growing epidemic. To conduct this study, patients who have undergone a coronary angiogram or a CT coronary angiogram that fall into the both extremes will be recruited and blood samples will be taken for the above analysis. These will be compared to a group of controls (low risk without disease and high risk with disease).Read full original descriptionShow less
Extremes of Coronary Artery Disease and Normality: Understanding Novel Causative and Protective Factors in the Development of Coronary Artery Disease (CAD Extremes)
In the field of cardiovascular medicine, there are two differing groups of patients that remain puzzling to clinicians: patients who are not expected to have coronary artery disease (CAD) yet are diagnosed with significant CAD; and those who are have multiple risk factors for CAD but do not have CAD. Bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. Prior work has identified multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis. The investigators hypothesize there are different molecular markers that confer protection or increased risk for CAD, some of which may be similar to bats. Thus, the aim of this study is to identify molecular markers that contribute to or are protective against acute coronary syndrome (ACS) through analyzing the genetics, peripheral blood and atherosclerotic samples from both extreme patient groups using single-cell RNA sequencing and multi-omics approach. In addition, novel anti-atherosclerotic mechanisms and factors from bat studies will be assessed in the human samples. Identification of novel targets that prevent or cause CAD has the potential to aid in the early identification of high-risk patients and development of new therapeutics to combat this growing epidemic. To conduct this study, patients who have undergone a coronary angiogram or a CT coronary angiogram that fall into the both extremes will be recruited and blood samples will be taken for the above analysis. These will be compared to a group of controls (low risk without disease and high risk with disease).
Inclusion: Group 1:; Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis >=50% in left main or >=70% in major epicardial vessel or major branches (LAD, LCX, RCA); AND all of the following; Age </= 45 for males and </= 50 for females; Absence of diabetes mellitus; Absence of tobacco use; No prior CVA or PAD; Group 2; Evidence of significant CAD; Coronary angiogram or CT coronary angiogram with documented stenosis >=50% in left main or >=70% in major epicardial vessel or major branches (LAD, LCX, RCA); AND all of the following; Age </= 45 for males and </= 50 for females; Absence of diabetes mellitus; Absence of tobacco use; No prior CVA or PAD; Group 3 1. Evidence of significant CAD with one of the following:; age>65; Diabetes mellitus; End Stage Renal Failure (ESRF); Framingham risk score >10%; Group 4; No evidence of significant CAD and all of the following; Age <55 for males, <65 for females; Absence of diabetes mellitus; Absence of CKD; Absence of tobacco use.
Exclusion: Prior history of cancer (excludes pre-cancerous lesions); Known autoimmune disease; Psychiatric illness; Chronic lung disease requiring long term medications or oxygen; Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV; Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes; Expected life expectancy less than 1 year; Inability to comply with study protocol.